Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991

被引：0
|
作者：
Sheppard, Karen E. [1 ]
Foo, Allen [1 ]
Young, Richard [1 ]
Waldeck, Kelly [1 ]
Pearson, Richard [1 ]
McArthur, Grant [1 ]
Christensen, James [2 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Australia
[2] Pfizer Oncol, Global Res & Dev, San Diego, CA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3416
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3416
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Genetic aberrations in the CDK4 pathway and association with innate resistance to PD-1 blockade in acral melanoma
    Yu, Jiayi
    Kong, Yan
    Chi, Zhihong
    Tang, Bixia
    Sheng, Xinan
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
    Garutti, Mattia
    Targato, Giada
    Buriolla, Silvia
    Palmero, Lorenza
    Minisini, Alessandro Marco
    Puglisi, Fabio
    CELLS, 2021, 10 (06)
  • [43] CDK4/6 as a therapeutic target in malignant melanoma
    Teh, Jessica L.
    Aplin, Andrew
    CANCER RESEARCH, 2015, 75
  • [44] Rarity of CDK4 germline mutations in familial melanoma
    Goldstein, AM
    Chidambaram, A
    Halpern, A
    Holly, EA
    Guerry, D
    Sagebiel, R
    Elder, DE
    Tucker, MA
    MELANOMA RESEARCH, 2002, 12 (01) : 51 - 55
  • [45] MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma
    Bustos, Matias A.
    Ono, Shigeshi
    Marzese, Diego M.
    Oyama, Takashi
    Iida, Yuuki
    Cheung, Garrett
    Nelson, Nellie
    Hsu, Sandy C.
    Yu, Qiang
    Hoon, Dave S. B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (09) : 1955 - 1964
  • [46] Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition
    Paternot, Sabine
    Raspe, Eric
    Meiller, Clement
    Tarabichi, Maxime
    Assie, Jean-Baptiste
    Libert, Frederick
    Remmelink, Myriam
    Bisteau, Xavier
    Pauwels, Patrick
    Blum, Yuna
    Le Stang, Nolwenn
    Tabone-Eglinger, Severine
    Galateau-Salle, Francoise
    Blanquart, Christophe
    Van Meerbeeck, Jan P.
    Berghmans, Thierry
    Jean, Didier
    Roger, Pierre P.
    MOLECULAR ONCOLOGY, 2024, 18 (04) : 866 - 894
  • [47] Improving immunotherapy with a combination of CDK4/6 inhibitor
    Yoshida, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S208 - S208
  • [48] Factors influencing CDK4/6 inhibitor adherence
    Clement, Navya
    Stutsky, Martha
    Gurubaran, Shreevidya Periyasamy Shanmugavel
    Smullen, Kate
    Argeros, Andrew
    Wolfe, Diane
    Donovan, Jennifer
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 : 24 - 24
  • [49] CDK4/6 inhibitor resistance: A bibliometric analysis
    Pang, Jiayuecheng
    Li, Hengyu
    Sheng, Yuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [50] Astex shapes CDK4/6 inhibitor for approval
    Peplow, Mark
    NATURE BIOTECHNOLOGY, 2017, 35 (05) : 395 - 396
12345